Atsushi Nohara

Dr. Atsushi Nohara

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
ANAtsushi Nohara
Atsushi Nohara
HTHayato Tada
Hayato Tada
MOMasatsune Ogura
Masatsune Ogura
SOSachiko Okazaki
Sachiko Okazaki
KOKoh Ono
Koh Ono
WJWelfare Of Japan
Welfare Of Japan
Familial hypercholesterolemia (FH) is an inherited disorder with retarded clearance of plasma LDL caused by mutations of the genes involved in the LDL receptor-mediated pathway and most of them exhibit autosomal dominant inheritance. Homozygotes of FH (HoFH) may have plasma LDL-C levels, which are at least twice as high as those of heterozygous FH (HeFH) and therefore four times higher than normal levels. Prevalence of HoFH had been estimated as 1 in 1,000,000 before but more recent genetic analysis surveys predict 1 in 170,000 to 300,000. Since LDL receptor activity is severely impaired, HoFH patients do not or very poorly respond to medications to enhance activity, such as statins, and have a poorer prognosis compared to HeFH. HoFH should therefore be clinically distinguished from HeFH. Thorough family studies and genetic analysis are recommended for their accurate diagnosis. Fatal cardiovascular complications could develop even in the first decade of life for HoFH, so aggressive lipid-lowering therapy should be initiated as early as possible. Direct removal of plasma LDL by lipoprotein apheresis has been the principal measure for these patients. However, this treatment alone may not achieve stable LDL-C target levels and combination with drugs should be considered. The lipid-lowering effects of statins and PCSK9 inhibitors substantially vary depending on the remaining LDL receptor activity of individual patients. On the other hand, the action an MTP inhibitor is independent of LDL receptor activity, and it is effective in most HoFH cases. This review summarizes the key clinical issues of HoFH as well as insurance coverage available under the Japanese public healthcare system.

1 October 2018 in Atherosclerosis
Verified
Journal Article
Open access
MHMariko Harada-Shiba
Mariko Harada-Shiba
JAJunya Ako
Junya Ako
HAHidenori Arai
Hidenori Arai
AHAtsushi Hirayama
Atsushi Hirayama
YMYoshitaka Murakami
Yoshitaka Murakami
MNMasato Nakamura
Masato Nakamura
Prevalence of familial hypercholesterolemia (FH), a common genetic disorder with a high risk for coronary artery disease (CAD), is high among CAD patients; however, data on FH prevalence among acute coronary syndrome (ACS) patients are limited. EXPLORE-J is the largest registry to diagnose FH among Japanese ACS patients using the 2012 Japan Atherosclerosis Society guidelines. This prospective study consecutively recruited patients between April 2015 and August 2016 at 59 sites. Low-density lipoprotein cholesterol (LDL-C) levels, family history of premature CAD, presence of tendon xanthomas, and Achilles tendon radiograms were recorded at baseline. The prevalence rate of FH in patients with ACS was estimated with 95% CI. Of 1944 analyzed patients (mean age, 66.0 years; men, 80.3%), 52 (2.7% [95% CI: 2.0-3.5]) had FH. Thirty-one (1.6%) had LDL-C ≥180 mg/dL and Achilles tendon thickness (ATT) ≥9 mm, 8 (0.4%) had LDL-C ≥180 mg/dL and family history of premature CAD, 10 (0.5%) had ATT ≥9 mm and family history of premature CAD, and 3 (0.2%) met all the criteria. FH patients were younger than those without FH (59.5 [12.5] vs. 66.2 [12.1] years; p < 0.001). More patients with premature ACS (men, <55 years; women, <65 years) than without (4.7% [95% CI: 2.9-7.2] vs. 2.1% [1.4-3.0]) had FH. FH prevalence is at least five-fold higher in ACS patients than in the general population, especially in patients with premature ACS onset and ATT ≥9 mm. FH screening in ACS patients is therefore clinically important and critical.

17 November 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Hayato TadaHayato Tada
Hayato Tada
ANAtsushi Nohara
Atsushi Nohara
MKMasa-Aki Kawashiri
Masa-Aki Kawashiri
Lipoproteins are a major risk factor for atherosclerotic cardiovascular diseases (ASCVD). Among the lipoproteins, low-density lipoproteins (LDL) have been shown to be causally associated with ASCVD development. In contrast, triglycerides or triglyceride-rich lipoproteins receive less attention than LDL because there is little definite evidence from randomized controlled trials. A Mendelian randomization study has recently been published in which a causal association could be estimated with observational datasets. Using such Mendelian randomization studies, ranging from common to rare genetic variations, triglycerides seem to be causally associated with ASCVD outcomes independent of LDL. Although the “causal association” of serum triglycerides and ASCVD is difficult to assert, accumulated evidence from clinical and Mendelian randomization studies, using common and rare genetic variations, strongly supports such an association. In this article, we provide a summary of investigations focusing on important causal associations between serum triglycerides and ASCVD from the clinical point of view.

1 April 2019 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
ANAtsushi Nohara
Atsushi Nohara
YOYoshihiko Otsubo
Yoshihiko Otsubo
KYKoji Yanagi
Koji Yanagi
MYMasayuki Yoshida
Masayuki Yoshida
KIKatsunori Ikewaki
Katsunori Ikewaki
AJAgnieszka Jurecka
Agnieszka Jurecka
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 January 2009 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
ANAtsushi Nohara
Atsushi Nohara
JKJunji Kobayashi
Junji Kobayashi
HMHiroshi Mabuchi
Hiroshi Mabuchi
Nuclear receptors are transcription factors that can be activated by specific ligands. Recent progress has shown that retinoid X receptor (RXR) and its heterodimerization partners, including peroxisome proliferator-activated receptors, regulate many important genes involved in energy homeostasis and atherosclerosis, and should be promising therapeutic targets of metabolic syndrome. RXR heterodimers regulate a number of complex cellular processes, and genetic studies of RXR heterodimers have provided important clinical information in addition to knowledge gained from basic research. Genetic variants of RXR heterodimers were screened and investigated, and some variants were shown to have a considerable impact on metabolic disorders, including phenotypic components of familial combined hyperlipidemia. The combined efforts of basic and clinical science regarding nuclear receptors have achieved significant progress in unraveling the inextricably linked control system of energy expenditure, lipid and glucose homeostasis, inflammation, and atherosclerosis. This review summarizes the current understanding regarding RXR heterodimers based on their human genetic variants, which will provide new clues to uncover the background of multifactorial disease, such as metabolic syndrome or familial combined hyperlipidemia.

1 May 2020 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
HTHayato Tada
Hayato Tada
MHMika Hori
Mika Hori
ANAkihiro Nomura
Akihiro Nomura
KHKazuyoshi Hosomichi
Kazuyoshi Hosomichi
ANAtsushi Nohara
Atsushi Nohara
MHMariko Harada-Shiba
Mariko Harada-Shiba